Posted by Michael Wonder on 15 Nov 2023
Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types
14 November 2023 - If approved, Tecentriq subcutaneous would be the first injectable PD-(L)1 cancer immunotherapy in the EU, cutting treatment time by approximately 80%.
Roche announced today that the EMA’s CHMP has recommended the approval of subcutaneous Tecentriq (atezolizumab).
